Natriuretic Peptides in Common Valvular Heart Disease

Journal of the American College of Cardiology

Volumn 55, Issue 19, 2010, Pages 2034-2048

  Steadman, Christopher D ^a   Ray, Simon ^b   Ng, Leong L ^a   McCann, Gerry P ^a  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

aortic; B type natriuretic peptide; biomarkers; mitral regurgitation; natriuretic peptides; stenosis

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; NATRIURETIC PEPTIDE TYPE C;

ACUTE CORONARY SYNDROME; AORTA STENOSIS; AORTA VALVE REPLACEMENT; CARDIOVASCULAR DISEASE; CLINICAL DECISION MAKING; DISEASE SEVERITY; EXERCISE; HEALTH STATUS; HEART FAILURE; HEART FUNCTION; HUMAN; MITRAL VALVE REGURGITATION; MITRAL VALVE REPAIR; POSTOPERATIVE PERIOD; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; REVIEW; SURVIVAL; SYMPTOM; VALVULAR HEART DISEASE;

AORTIC VALVE STENOSIS; BIOLOGICAL MARKERS; HUMANS; MITRAL VALVE INSUFFICIENCY; NATRIURETIC PEPTIDES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 77951640028     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.02.021     Document Type: Review

References (95)

1. Nkomo V.T., Gardin J.M., Skelton T.N., Gottdiener J.S., Scott C.G., and Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet 368 (2006) 1005-1011
2. Nielsen L.S., Svanegaard J., Klitgaard N.A., and Egeblad H. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. Eur J Heart Fail 6 (2004) 63-70
3. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., and Richards A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 (2000) 1126-1130
4. Jourdain P., Jondeau G., Funck F., et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 49 (2007) 1733-1739
5. Khan S.Q., Dhillon O., Kelly D., et al. Plasma N-terminal B-type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 51 (2008) 1857-1864
6. Khan S.Q., Narayan H., Ng K.H., et al. N-terminal pro-B-type natriuretic peptide complements the GRACE risk score in predicting early and late mortality following acute coronary syndrome. Clin Sci (Lond) 117 (2009) 31-39
7. Richards A.M., Nicholls M.G., Yandle T.G., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 97 (1998) 1921-1929
8. Mair J. Biochemistry of B-type natriuretic peptide-where are we now?. Clin Chem Lab Med 46 (2008) 1507-1514
9. Gardner D.G. Molecular and cellular biology of the natriuretic peptides. Heart Failure 12 (1996) 37-54
10. Daniels L.B., and Maisel A.S. Natriuretic peptides. J Am Coll Cardiol 50 (2007) 2357-2368
11. de Lemos J.A., McGuire D.K., and Drazner M.H. B-type natriuretic peptide in cardiovascular disease. Lancet 362 (2003) 316-322
12. Minamino N., Makino Y., Tateyama H., Kangawa K., and Matsuo H. Characterization of immunoreactive human C-type natriuretic peptide in brain and heart. Biochem Biophys Res Commun 179 (1991) 535-542
13. Onuoha G.N., Nicholls D.P., Patterson A., and Beringer T. Neuropeptide secretion in exercise. Neuropeptides 32 (1998) 319-325
14. Sumida H., Yasue H., Yoshimura M., et al. Comparison of secretion pattern between A-type and B-type natriuretic peptides in patients with old myocardial infarction. J Am Coll Cardiol 25 (1995) 1105-1110
15. Yasue H., Yoshimura M., Sumida H., et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90 (1994) 195-203
16. Yoshimura M., Yasue H., Okumura K., et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 87 (1993) 464-469
17. Qi W., Mathisen P., Kjekshus J., et al. Natriuretic peptides in patients with aortic stenosis. Am Heart J 142 (2001) 725-732
18. Koller K.J., and Goeddel D.V. Molecular biology of the natriuretic peptides and their receptors. Circulation 86 (1992) 1081-1088
19. Clarkson P.B., Wheeldon N.M., MacLeod C., Coutie W., and MacDonald T.M. Brain natriuretic peptide: effect on left ventricular filling patterns in healthy subjects. Clin Sci (Lond) 88 (1995) 159-164
20. Ogawa Y., Tamura N., Chusho H., and Nakao K. Brain natriuretic peptide appears to act locally as an antifibrotic factor in the heart. Can J Physiol Pharmacol 79 (2001) 723-729
21. Tamamori M., Ito H., Hiroe M., Marumo F., and Hata R.I. Stimulation of collagen synthesis in rat cardiac fibroblasts by exposure to hypoxic culture conditions and suppression of the effect by natriuretic peptides. Cell Biol Int 21 (1997) 175-180
22. Peltonen T.O., Taskinen P., Soini Y., et al. Distinct downregulation of C-type natriuretic peptide system in human aortic valve stenosis. Circulation 116 (2007) 1283-1289
23. Edwards M.B., and Taylor K.M. A profile of valve replacement surgery in the UK (1986-1997): a study from the UK Heart Valve Registry. J Heart Valve Dis 8 (1999) 697-701
24. Lindblom D., Lindblom U., Qvist J., and Lundstrom H. Long-term relative survival rates after heart valve replacement. J Am Coll Cardiol 15 (1990) 566-573
25. Ross Jr. J., and Braunwald E. Aortic stenosis. Circulation 38 (1968) 61-67
26. McGoon D.C., Ellis Jr. F.H., and Kirklin J.W. Late results of operation for acquired aortic valvular disease. Circulation 31 Suppl (1965) 108-116
27. Otto C.M., Burwash I.G., Legget M.E., et al. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation 95 (1997) 2262-2270
28. Rosenhek R., Binder T., Porenta G., et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 343 (2000) 611-617
29. Amato M.C., Moffa P.J., Werner K.E., and Ramires J.A. Treatment decision in asymptomatic aortic valve stenosis: role of exercise testing. Heart 86 (2001) 381-386
30. Lund O., Nielsen T.T., Emmertsen K., et al. Mortality and worsening of prognostic profile during waiting time for valve replacement in aortic stenosis. Thorac Cardiovasc Surg 44 (1996) 289-295
31. Das P., Rimington H., and Chambers J. Exercise testing to stratify risk in aortic stenosis. Eur Heart J 26 (2005) 1309-1313
32. Pellikka P.A., Sarano M.E., Nishimura R.A., et al. Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation 111 (2005) 3290-3295
33. Lancellotti P., Lebois F., Simon M., Tombeux C., Chauvel C., and Pierard L.A. Prognostic importance of quantitative exercise Doppler echocardiography in asymptomatic valvular aortic stenosis. Circulation 112 (2005) I377-I382
34. Rosenhek R., Rader F., Loho N., et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 110 (2004) 1291-1295
35. Bonow R.O., Carabello B.A., Chatterjee K., et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 52 (2008) e1-e142
36. Vahanian A., Baumgartner H., Bax J., et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 28 (2007) 230-268
37. Dal-Bianco J.P., Khandheria B.K., Mookadam F., Gentile F., and Sengupta P.P. Management of asymptomatic severe aortic stenosis. J Am Coll Cardiol 52 (2008) 1279-1292
38. Prasad N., Bridges A.B., Lang C.C., et al. Brain natriuretic peptide concentrations in patients with aortic stenosis. Am Heart J 133 (1997) 477-479
39. Talwar S., Downie P.F., Squire I.B., Davies J.E., Barnett D.B., and Ng L.L. Plasma N-terminal pro BNP and cardiotrophin-1 are elevated in aortic stenosis. Eur J Heart Fail 3 (2001) 15-19
40. Cemri M., Arslan U., Kocaman S., and Cengel A. Relationship between N-terminal pro-B type natriuretic peptide and extensive echocardiographic parameters in mild to moderate aortic stenosis. J Postgrad Med 54 (2008) 12-16
41. Ikeda T., Matsuda K., Itoh H., et al. Plasma levels of brain and atrial natriuretic peptides elevate in proportion to left ventricular end-systolic wall stress in patients with aortic stenosis. Am Heart J 133 (1997) 307-314
42. Nordmeyer J., Eder S., Mahmoodzadeh S., et al. Upregulation of myocardial estrogen receptors in human aortic stenosis. Circulation 110 (2004) 3270-3275
43. Orlowska-Baranowska E., Baranowski R., Greszata L., and Stepinska J. Brain natriuretic peptide as a marker of left ventricular hypertrophy in patients with aortic stenosis. J Heart Valve Dis 17 (2008) 598-605
44. Neverdal N.O., Knudsen C.W., Husebye T., et al. The effect of aortic valve replacement on plasma B-type natriuretic peptide in patients with severe aortic stenosis-one year follow-up. Eur J Heart Fail 8 (2006) 257-262
45. Weber M., Hausen M., Arnold R., et al. Prognostic value of N-terminal pro-B-type natriuretic peptide for conservatively and surgically treated patients with aortic valve stenosis. Heart 92 (2006) 1639-1644
46. Antonini-Canterin F., Popescu B.A., Popescu A.C., et al. Heart failure in patients with aortic stenosis: clinical and prognostic significance of carbohydrate antigen 125 and brain natriuretic peptide measurement. Int J Cardiol 128 (2008) 406-412
47. Vanderheyden M., Goethals M., Verstreken S., et al. Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy. J Am Coll Cardiol 44 (2004) 2349-2354
48. Gerber I.L., Stewart R.A., Legget M.E., et al. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation 107 (2003) 1884-1890
49. Poulsen S.H., Sogaard P., Nielsen-Kudsk J.E., and Egeblad H. Recovery of left ventricular systolic longitudinal strain after valve replacement in aortic stenosis and relation to natriuretic peptides. J Am Soc Echocardiogr 20 (2007) 877-884
50. Faggiano P., Rusconi C., Ghizzoni G., and Sabatini T. Left ventricular remodeling and function in adult aortic stenosis. Angiology 45 (1994) 1033-1038
51. Bergler-Klein J., Klaar U., Heger M., et al. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation 109 (2004) 2302-2308
52. Pedrazzini G.B., Masson S., Latini R., et al. Comparison of brain natriuretic peptide plasma levels versus logistic EuroSCORE in predicting in-hospital and late postoperative mortality in patients undergoing aortic valve replacement for symptomatic aortic stenosis. Am J Cardiol 102 (2008) 749-754
53. Galema T.W., Yap S.C., Geleijnse M.L., et al. Early detection of left ventricular dysfunction by Doppler tissue imaging and N-terminal pro-B-type natriuretic peptide in patients with symptomatic severe aortic stenosis. J Am Soc Echocardiogr 21 (2008) 257-261
54. Nagueh S.F., Middleton K.J., Kopelen H.A., Zoghbi W.A., and Quinones M.A. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 30 (1997) 1527-1533
55. Poh K.K., Chan M.Y., Yang H., Yong Q.W., Chan Y.H., and Ling L.H. Prognostication of valvular aortic stenosis using tissue Doppler echocardiography: underappreciated importance of late diastolic mitral annular velocity. J Am Soc Echocardiogr 21 (2008) 475-481
56. Grossman W., Jones D., and McLaurin L.P. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 56 (1975) 56-64
57. Nessmith M.G., Fukuta H., Brucks S., and Little W.C. Usefulness of an elevated B-type natriuretic peptide in predicting survival in patients with aortic stenosis treated without surgery. Am J Cardiol 96 (2005) 1445-1448
58. Lim P., Monin J.L., Monchi M., et al. Predictors of outcome in patients with severe aortic stenosis and normal left ventricular function: role of B-type natriuretic peptide. Eur Heart J 25 (2004) 2048-2053
59. Prasad S.K., Dargie H.J., Smith G.C., et al. Comparison of the dual receptor endothelin antagonist enrasentan with enalapril in asymptomatic left ventricular systolic dysfunction: a cardiovascular magnetic resonance study. Heart 92 (2006) 798-803
60. Wagner J.A., Stork S., Weidemann F., et al. Natriuretic peptides and myocardial oxygen supply-to-demand ratio in patients with aortic stenosis. Eur J Clin Invest 37 (2007) 463-471
61. Weber M., Arnold R., Rau M., et al. Relation of N-terminal pro-B-type natriuretic peptide to severity of valvular aortic stenosis. Am J Cardiol 94 (2004) 740-745
62. Van Pelt N.C., Kerr A.J., Legget M.E., et al. Increased B-type natriuretic peptide is associated with an abnormal blood pressure response to exercise in asymptomatic aortic stenosis. Int J Cardiol 127 (2008) 313-320
63. Van Pelt N.C., Stewart R.A., Legget M.E., et al. Longitudinal left ventricular contractile dysfunction after exercise in aortic stenosis. Heart 93 (2007) 732-738
64. Kaden J.J., Eckert J.P., Poerner T., et al. Prevalence of atherosclerosis of the coronary and extracranial cerebral arteries in patients undergoing aortic valve replacement for calcified stenosis. J Heart Valve Dis 15 (2006) 165-168
65. Kupari M., Turto H., Lommi J., Makijarvi M., and Parikka H. Transcardiac gradients of N-terminal B-type natriuretic peptide in aortic valve stenosis. Eur J Heart Fail 7 (2005) 809-814
66. Gerber I.L., Legget M.E., West T.M., Richards A.M., and Stewart R.A. Usefulness of serial measurement of N-terminal pro-brain natriuretic peptide plasma levels in asymptomatic patients with aortic stenosis to predict symptomatic deterioration. Am J Cardiol 95 (2005) 898-901
67. Feuchtner G.M., Muller S., Grander W., et al. Aortic valve calcification as quantified with multislice computed tomography predicts short-term clinical outcome in patients with asymptomatic aortic stenosis. J Heart Valve Dis 15 (2006) 494-498
68. Dichtl W., Alber H.F., Feuchtner G.M., et al. Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg). Am J Cardiol 102 (2008) 743-748
69. Monin J.L., Lancellotti P., Monchi M., et al. Risk score for predicting outcome in patients with asymptomatic aortic stenosis. Circulation 120 (2009) 69-75
70. Georges A., Forestier F., Valli N., Plogin A., Janvier G., and Bordenave L. Changes in type B natriuretic peptide (BNP) concentrations during cardiac valve replacement. Eur J Cardiothorac Surg 25 (2004) 941-945
71. Kostopanagiotou G., Apostolakis E., Theodoraki K., et al. Perioperative changes in atrial natriuretic peptide plasma levels associated with mitral and aortic valve replacement. J Cardiothorac Vasc Anesth 18 (2004) 30-33
72. Weber M., Arnold R., Rau M., et al. Relation of N-terminal pro B-type natriuretic peptide to progression of aortic valve disease. Eur Heart J 26 (2005) 1023-1030
73. Qi W., Mathisen P., Kjekshus J., et al. The effect of aortic valve replacement on N-terminal natriuretic propeptides in patients with aortic stenosis. Clin Cardiol 25 (2002) 174-180
74. Gardner D.G. Natriuretic peptides: markers or modulators of cardiac hypertrophy?. Trends Endocrinol Metab 14 (2003) 411-416
75. Yilmaz M.B., Erbay A.R., Balci M., et al. Atrial natriuretic peptide predicts impaired atrial remodeling and occurrence of late postoperative atrial fibrillation after surgery for symptomatic aortic stenosis. Cardiology 105 (2006) 207-212
76. Bergler-Klein J., Mundigler G., Pibarot P., et al. B-type natriuretic peptide in low-flow, low-gradient aortic stenosis: relationship to hemodynamics and clinical outcome: results from the Multicenter Truly or Pseudo-Severe Aortic Stenosis (TOPAS) study. Circulation 115 (2007) 2848-2855
77. Weidemann F., Herrmann S., Stork S., et al. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation 120 (2009) 577-584
78. Gaasch W.H., and Meyer T.E. Left ventricular response to mitral regurgitation: implications for management. Circulation 118 (2008) 2298-2303
79. Avierinos J.F., Gersh B.J., Melton III L.J., et al. Natural history of asymptomatic mitral valve prolapse in the community. Circulation 106 (2002) 1355-1361
80. Ling L.H., Enriquez-Sarano M., Seward J.B., et al. Clinical outcome of mitral regurgitation due to flail leaflet. N Engl J Med 335 (1996) 1417-1423
81. Shuhaiber J., and Anderson R.J. Meta-analysis of clinical outcomes following surgical mitral valve repair or replacement. Eur J Cardiothorac Surg 31 (2007) 267-275
82. Enriquez-Sarano M., Avierinos J.F., Messika-Zeitoun D., et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med 352 (2005) 875-883
83. Rosenhek R., Rader F., Klaar U., et al. Outcome of watchful waiting in asymptomatic severe mitral regurgitation. Circulation 113 (2006) 2238-2244
84. Bridgewater B., Hooper T., Munsch C., et al. Mitral repair best practice: proposed standards. Heart 92 (2006) 939-944
85. Sutton T.M., Stewart R.A., Gerber I.L., et al. Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J Am Coll Cardiol 41 (2003) 2280-2287
86. Detaint D., Messika-Zeitoun D., Chen H.H., et al. Association of B-type natriuretic peptide activation to left ventricular end-systolic remodeling in organic and functional mitral regurgitation. Am J Cardiol 97 (2006) 1029-1034
87. Dini F.L., Fontanive P., Conti U., Andreini D., Cabani E., and De Tommasi S.M. Plasma N-terminal protype-B natriuretic peptide levels in risk assessment of patients with mitral regurgitation secondary to ischemic and nonischemic dilated cardiomyopathy. Am Heart J 155 (2008) 1121-1127
88. Lancellotti P., Cosyns B., and Pierard L.A. Dynamic left ventricular dyssynchrony contributes to B-type natriuretic peptide release during exercise in patients with systolic heart failure. Europace 10 (2008) 496-501
89. Pizarro R., Bazzino O.O., Oberti P.F., et al. Prospective validation of the prognostic usefulness of brain natriuretic peptide in asymptomatic patients with chronic severe mitral regurgitation. J Am Coll Cardiol 54 (2009) 1099-1106
90. Yusoff R., Clayton N., Keevil B., Morris J., and Ray S. Utility of plasma N-terminal brain natriuretic peptide as a marker of functional capacity in patients with chronic severe mitral regurgitation. Am J Cardiol 97 (2006) 1498-1501
91. Detaint D., Messika-Zeitoun D., Avierinos J.F., et al. B-type natriuretic peptide in organic mitral regurgitation: determinants and impact on outcome. Circulation 111 (2005) 2391-2397
92. Kerr A.J., Raffel O.C., Whalley G.A., Zeng I., and Stewart R.A. Elevated B-type natriuretic peptide despite normal left ventricular function on rest and exercise stress echocardiography in mitral regurgitation. Eur Heart J 29 (2008) 363-370
93. Potocki M., Mair J., Weber M., et al. Relation of N-terminal pro-B-type natriuretic peptide to symptoms, severity, and left ventricular remodeling in patients with organic mitral regurgitation. Am J Cardiol 104 (2009) 559-564
94. Shimamoto K., Kusumoto M., Sakai R., et al. Usefulness of the brain natriuretic peptide to atrial natriuretic peptide ratio in determining the severity of mitral regurgitation. Can J Cardiol 23 (2007) 295-300
95. Ho S.F., O'Mahony M.S., Steward J.A., Breay P., Buchalter M., and Burr M.L. Dyspnoea and quality of life in older people at home. Age Ageing 30 (2001) 155-159